Empowered Funds LLC Boosts Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Empowered Funds LLC increased its Edwards Lifesciences stake by 154.6% in the first quarter, purchasing 49,800 additional shares for a total holding of 82,019 shares valued at $6.6 million. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences reported quarterly EPS of $0.78 and revenue of $1.74 billion, exceeding analyst expectations, while revenue rose 13.6% year over year. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77 and full-year guidance of $2.95–$3.05.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $100.27, although company insiders have sold approximately $2.27 million in stock over the past 90 days.

Empowered Funds LLC boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 154.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,019 shares of the medical research company's stock after buying an additional 49,800 shares during the period. Empowered Funds LLC's holdings in Edwards Lifesciences were worth $6,568,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth $266,000. NewEdge Advisors LLC raised its position in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock worth $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. raised its position in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock worth $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC boosted its stake in Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock worth $5,417,000 after purchasing an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina boosted its stake in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock worth $21,028,000 after purchasing an additional 1,065 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $91.51 on Friday. The business has a 50-day simple moving average of $88.73 and a two-hundred day simple moving average of $84.37. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The stock has a market cap of $52.69 billion, a price-to-earnings ratio of 52.59, a PEG ratio of 2.30 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business's quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on EW shares. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Evercore reiterated an "outperform" rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and increased their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Saturday, July 4th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company's stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company's stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company's stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 26,190 shares of company stock worth $2,269,697. Company insiders own 0.31% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source